| 000 | 01778 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518001731.0 | ||
| 264 | 0 | _c20190604 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1651-226X | ||
| 024 | 7 |
_a10.1080/0284186X.2018.1518592 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLangenberg, S M C H | |
| 245 | 0 | 0 |
_aCaregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden. _h[electronic resource] |
| 260 |
_bActa oncologica (Stockholm, Sweden) _cFeb 2019 |
||
| 300 |
_a191-199 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBurnout, Psychological _xepidemiology |
| 650 | 0 | 4 |
_aCaregivers _xpsychology |
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aCross-Sectional Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aGastrointestinal Stromal Tumors _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aSocial Support |
| 650 | 0 | 4 |
_aStress, Psychological _xepidemiology |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 700 | 1 | _aReyners, A K L | |
| 700 | 1 | _aWymenga, A N M | |
| 700 | 1 | _aSieling, G C M | |
| 700 | 1 | _aVeldhoven, C M M | |
| 700 | 1 | _avan Herpen, C M L | |
| 700 | 1 | _aPrins, J B | |
| 700 | 1 | _avan der Graaf, W T A | |
| 773 | 0 |
_tActa oncologica (Stockholm, Sweden) _gvol. 58 _gno. 2 _gp. 191-199 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/0284186X.2018.1518592 _zAvailable from publisher's website |
| 999 |
_c28899372 _d28899372 |
||